Cyp asx

Market data is provided and copyrighted by Thomson Reuters and Morningstar. Click for restrictions.

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast MCA to manufacture cell therapy products, including mesenchymal stem cells , on a commercial scale. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other. Financial Times Close. Search the FT Search. Show more World link World.

Cyp asx

Morningstar Investor users sign in here. Skip to Content. Market Centre. United States. Market Report. ASX Market Report. Roundup of ASX market movements. Global Market Report. Roundup of Global market movements. Market Calendar.

All rights reserved. In particular, the content does not constitute any form of advice, cyp asx, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making or refraining from making any specific investment or other decisions, cyp asx. Financial Times Close.

Cynata Therapeutics Limited. Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. About the company. CYP Stock Overview Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. Revenue is forecast to grow

Financial Times Close. Search the FT Search. Show more World link World. Show more US link US. Show more Companies link Companies. Show more Tech link Tech. Show more Markets link Markets. Show more Opinion link Opinion. Show more Personal Finance link Personal Finance.

Cyp asx

Key events shows relevant news articles on days with large price movements. Mesoblast Ltd. MSB 7. Starpharma Holdings Ltd. SPL 3. Anteris Technologies Ltd. AVR 0. Regeneus Ltd. RGS 0.

Mens gold ring with ruby stone

Information Services. Morningstar equity research methodology. Why list on ASX. Show more Personal Finance link Personal Finance. Cann Group Ltd. Institutional shareholders Top holders Movers. Cynata Therapeutics Limited. Show more Opinion link Opinion. New major risk - Financial position Aug This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities. Start investing. Cancel Continue.

See all ideas. See all brokers.

Cynata Therapeutics Limited Fundamentals Summary. Our Solutions. For Asset Managers. ASX regulatory framework. Learn to invest in Is CYP overvalued? Morningstar Investor users sign in here. Any information that you receive via FT. Show more Markets link Markets. ASX Compliance. For Individual Investors. Morningstar Indexes. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology.